PDCD1LG2 and neoplasm: Chemotherapy can potentiate the efficacy of immune checkpoint inhibitor (ICI) therapy by promoting the release of neoantigens, modifying the TME through the depletion of Tregs and MDSCs, and reducing PD-L2 expression on DCs and tumor cells.